{"abstract": "Amylin is working with Credit Suisse, Goldman Sachs and the law firm Skadden, Arps, Slate, Meagher & Flom, according to a person briefed on the matter, who added that no sale is imminent.", "web_url": "https://dealbook.nytimes.com/2012/04/22/amylin-said-to-pursue-a-sale/", "snippet": "Amylin is working with Credit Suisse, Goldman Sachs and the law firm Skadden, Arps, Slate, Meagher & Flom, according to a person briefed on the matter, who added that no sale is imminent.", "lead_paragraph": "Amylin Pharmaceuticals is seeking a potential buyer, after it rebuffed an unsolicited $3.5 billion takeover offer from Bristol-Myers Squibb earlier this year, a person briefed on the matter said Sunday.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Amylin Is Said to Pursue a Sale", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "persons", "value": "Icahn, Carl C", "rank": 1, "major": "N"}, {"name": "organizations", "value": "AMYLIN PHARMACEUTICALS INC", "rank": 2, "major": "N"}, {"name": "organizations", "value": "Bristol Myers Squibb Company", "rank": 3, "major": "N"}], "pub_date": "2012-04-23T00:54:43+0000", "document_type": "article", "news_desk": "", "section_name": "Business Day", "byline": {"original": "By Michael J. de la Merced", "person": [{"firstname": "Michael", "middlename": "J.", "lastname": "de la Merced", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/8438b35f-7c6e-5b93-bff0-435f736866b6", "word_count": 300, "uri": "nyt://article/8438b35f-7c6e-5b93-bff0-435f736866b6"}